Últimas noticias sobre Lifevantage (NASDAQ:LFVN) Bolsa

Lifevantage

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Movimiento de acciones

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHL

ASYS

EFXT

GNFT

HYFM

LFVN

MTUS

RSLS

RVSB

STSS

SUNE

VEEE

VERO

WHLR

ReShape Lifesciences firma acuerdo exclusivo con Motion Informatics y dispara sus acciones antes de la apertura de mercado.

Acciones de ReShape Lifesciences (RSLS) se disparan un 82%; Aquí están 20 acciones que se mueven en premercado

Short Ideas

Descubre cómo dos acciones del sector de productos básicos alertan a inversores con altos valores de RSI este 2025.

2 acciones de productos básicos de consumo que podrían caer en el 1T

NAPA

PAVS

3 acciones sobrecompradas del sector de bienes de consumo con RSI sobre 70. ¿Son una señal de advertencia para inversores basados en impulso?

3 acciones sobrecompradas en bienes de consumo: ¿Oportunidad o advertencia?

Lifevantage Corp

WIIM

COTY

FRPT

LOCL

MGRX

PFGC

USFD

Shares of companies within the broader consumer staples sector are trading lower as stocks pull back after surging Wednesday following President Trump's tariff pause announcement.

Shares of ReShape Lifesciences Inc. (NASDA: RSLS) rose sharply in today's pre-market trading after the company announced a partnership with Motion Informatics to exclusively import and distribute neuromuscular rehabilitation <a href="https://www.benzinga.com/quote/RSLS">devices in the US</a>.
ReShape Lifesciences shares jumped 82.2% to $0.6232 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) rose 111.7% to $5.02 in pre-market trading. On March 4, Wheeler Real Estate IT posted fourth-quarter FFO of $18.48, down from $182.82 in the year-ago period. The company's sales rose to $27.59 million from $26.21 million.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) surged 43.6% to $0.0201 in pre-market trading after dipping 17% on Wednesday.</li>
<li>Riverview Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSB#NASDAQ">RVSB</a>) gained 33.5% to $8.00 in pre-market. On April 2, Riverview Bancorp declared a quarterly cash dividend of 2 cents per share.</li>
<li>Hydrofarm Holdings Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) rose 34.4% to $2.26 in pre-market trading after gaining 5% on Wednesday.</li>
<li>SUNation Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) rose 29.9% to $0.0256 in pre-market trading. SUNation Energy strengthened its financial position via recently completed financings and debt reduction</li>
<li>Genfit S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) gained 24.7% to $3.31 in pre-market trading after dipping more than 19% on Wednesday.</li>
<li>LakeShore Biopharma Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) gained 20.7% to $2.08 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) surged 15.8% to $4.30 in pre-market trading after gaining more than 12% on Wednesday.</li>
<li>Enerflex Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFXT#NYSE">EFXT</a>) jumped 13% to $8.00 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Rithm Property Trust Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPT#NYSE">RPT</a>) fell 55.7% to $1.20 in pre-market trading after gaining 12% on Wednesday.</li>
<li>Venus Concept Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares tumbled 47.9% to $4.65 in pre-market trading after the company announced a $1.1 million registered direct offering of common stock priced at-the-market under Nasdaq rules.</li>
<li>Damon Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) fell 46.5% to $0.0065 in today's pre-market trading.</li>
<li>Twin Vee Powercats Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares fell 31.7% to $2.80 in pre-market trading. Twin Vee PowerCats recently announced a 1-for-10 reverse stock split.</li>
<li>LifeVantage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) fell 31.4% to $10.50 in pre-market trading after gaining 10% on Wednesday.</li>
<li>Greenfire Resources Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) shares fell 31.1% to $3.50 in pre-market trading.</li>
<li>Upstream Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) shares dipped 29.6% to $4.60 in pre-market trading after gaining 8% on Wednesday. Upstream Bio, last month, reported worse-than-expected third-quarter sales results.</li>
<li>Antelope Enterprise Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) fell 28.1% to $3.20 in pre-market trading after jumping 104% on Wednesday.</li>
<li>Metallus Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTUS#NYSE">MTUS</a>) dipped 25.3% to $9.50 in pre-market trading after gaining 11% on Wednesday.</li>
<li>Amtech Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) declined 8% to $3.92 in pre-market trading as the company cut its revenue forecast for the second quarter from $21 million-$23 million to $15 million-$16 million.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket

Biotech

General

AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RHHBY

TERN

VANI

VKTX

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Michael Beindorff, Director at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported an insider sell on February 13, according to a new SEC filing. 
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914625000019//Archives/edgar/data/849146/000084914625000019/0000849146-25-000019-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Beindorff sold 5,850 shares of Lifevantage. The total transaction value is $114,309.
As of Thursday morning, Lifevantage shares are down by 5.58%, currently priced at $18.28.
<h3>Delving into Lifevantage's Background</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage's Economic Impact: An Analysis</h3>
Decline in Revenue: Over the 3 months period, Lifevantage faced challenges, resulting in a decline of approximately -8.08% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 79.9%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS reflects a decline, falling below the industry average with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.48, Lifevantage faces challenges in effectively managing its debt levels, indicating potential financial strain.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: Lifevantage's current Price to Earnings (P/E) ratio of 33.96 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 1.2, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 16.55, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Decision: Michael Beindorff Offloads $114K Worth Of Lifevantage Stock

Making a noteworthy insider sell on February 13, Cynthia Latham, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), is reported in the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914625000020//Archives/edgar/data/849146/000084914625000020/0000849146-25-000020-index.htm">U.S. Securities and Exchange Commission</a> on Thursday outlined that Latham executed a sale of 4,450 shares of Lifevantage with a total value of $89,089.
During Thursday's morning session, Lifevantage shares down by 1.81%, currently priced at $19.01.
<h3>Get to Know Lifevantage Better</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage's Financial Performance</h3>
Decline in Revenue: Over the 3 months period, Lifevantage faced challenges, resulting in a decline of approximately -8.08% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 79.9%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: Lifevantage's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.48, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 33.96 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.2, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 16.55, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Important Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Unloading: Cynthia Latham Sells $89K Worth Of Lifevantage Shares

Revealing a significant insider sell on February 13, Raymond B Greer, Director at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914625000021//Archives/edgar/data/849146/000084914625000021/0000849146-25-000021-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Greer sold 8,000 shares of Lifevantage. The total transaction value is $161,221.
The latest market snapshot at Thursday morning reveals Lifevantage shares down by 1.81%, trading at $19.01.
<h3>Get to Know Lifevantage Better</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>A Deep Dive into Lifevantage's Financials</h3>
Revenue Growth: Lifevantage's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -8.08%. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 79.9%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: Lifevantage's debt-to-equity ratio surpasses industry norms, standing at 0.48. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 33.96 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 1.2, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 16.55 reflects market recognition of Lifevantage's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lifevantage Director Trades $161K In Company Stock

Lifevantage shares are trading lower following Q2 financial results.

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) announced its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.
Revenue was up $16.14 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Lifevantage's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Breakdown: Lifevantage Q2

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) announced its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.
Revenue was up $16.14 million from the same period last year.
<h3>Previous Earnings Records</h3>
In the previous quarter, the company missed on EPS by $0.0, resulting in a 0.0% increase change in the share price the following day.
Here's a look at Lifevantage's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lifevantage: Q2 Earnings Insights

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported its Q2 earnings results on Wednesday, February 5, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.
Revenue was up $16.14 million from the same period last year.
<h3>Historical Earnings Summary</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Lifevantage's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lifevantage Q2 Earnings Assessment

The earnings results for Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) for Q2 were made public on Wednesday, February 5, 2025 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Lifevantage beat estimated earnings by 69.0%, reporting an EPS of $0.22 versus an estimate of $0.13.
Revenue was up $16.14 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company missed on EPS by $0.0 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Lifevantage's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.15</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>49.80M</td>
<td>50.95M</td>
<td>52.18M</td>
<td>54.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>47.21M</td>
<td>48.93M</td>
<td>48.24M</td>
<td>51.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Lifevantage <a href="https://www.benzinga.com/quote/LFVN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lifevantage Earnings Report: Q2 Overview

Lifevantage shares are trading lower. The company reported Q2 financial results.

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) affirms FY2025 sales outlook from $235.00 million-245.00 million to $235.00 million-245.00 million vs $238.48 million estimate.

Guidance

Lifevantage Affirms FY2025 Sales Guidance from $235.00M-245.00M to $235.00M-245.00M vs $238.48M Est

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.13 by 69.23 percent. This is a 120 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $67.76 million which beat the analyst consensus estimate of $67.39 million by 0.55 percent. This is a 31.26 percent increase over sales of $51.62 million the same period last year.

Earnings Beats

Lifevantage Q2 Adj $0.22 Beats $0.13 Estimate, Sales $67.76M Beat $67.39M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

Earnings Scheduled For February 5, 2025

<a href="https://www.globenewswire.com/Tracker?data=gwMH3B4Mtk6zsfMyNNHclGKg75ZpKpLzvyjPTOraiSWBqdNGO86iEObjelMlG7V3ynU183ZUCXrCrVdfwitv8WYas8qIx-n6vApENuMPv8eu0o5hC5I5R6eNYTC9FgG8BgC5gNw3LK74Tbqjpep5ZF64p7HSayWnDUrsVaj-kCpN3plEahB6rCmNAnaqTUTyG6ur--0jgBJH1oWZXTomxPIqsGNxYe8sOljRdf4RKeq639PT-lvEjkkvgVQZZ39CrDff_y2a9ske4V7QvFzvuMb4zeGNFJJHCX31TIjxQ_SIx3MgdM17XwjKQ9zJNx705vmVf9AO-_GNvvEoSicoc4suZDHS3bkoMcFAeCc31k1xcXTpnEfIllnHxx7EG67XEdaUOLS8jH9i3WcO-2MDDG5nYVeqvWTj7VWSeh5FYXrpa90Ot9IL145483aaQiUsavMmpoSeuLB11RNjVp-we0VJWGsLFPhhr7dMkkLfA6zCdlf7vgAmENB32mydv36vErBHSt6-fJCH2bB9EF-gEUnwqsyktuQ6JFbgdmp_m42uXMa445XN_NH-1ibQ9BOwl884Z9ehQ9MLwQVOn297kg==">LifeVantage Corporation</a><a href="https://www.globenewswire.com/Tracker?data=Asex0NnVLZW4-GgYGWwPWz1p1VgTONiNFv8H17XLaYyflNXPQy6eR1W-eEGy3EB731a-vldwrtIA-sIZsbHSYwh_2Cj9uBKRENRNS2QTWOymJSN_trhIboSnlx0dRgSWpHcEkteYxHqXh7_bN_WcnjCBqHZgg1YFs2tBcERBcm7l-QU9oPIlyHTSTJrmuMq3SWcnW2REk8QkpgdJVdvuLGk62Leyk-k4a3F7VUzc3mlxUwRksCGDNs3vDgI4tj1tJ4iFkJDtAfdHlRWqMCumQ68x7UdtJv0htEO9H9WDtOGndrmRHH0mDDjgj0QoIBvUUfG2TFRjXQiv5loebBxlXR74ls5j11XY2wCU4hUuEhgLSoqYVts3VALscCwNuZ6beqQd0jR5BY55EVeFkvFx9n2BcNQPfD8dsl0Ak-Ec0G6N46_pTKuuTX1424i1W2h5MdhVXIlBZxBJLLqM-ipLhQTUv5xIAKWWAtg94Dcu6hO7R0jN7AjAtr5yzc5fiacmi3qGS_twKqKPNF_7XxkAJNRBRS3ICyQNy6iN9uzf0WU=">&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the completion of an international in vitro cell study that investigated the effects of its international formulation for the <a href="https://www.globenewswire.com/Tracker?data=4RuCMkUyZ8cIhcCPRa6OUEHlQxhJ9T8Ko5KBDl48fq56IrkMD1d3V_QN4szyzBJTG7-0pdp1kq_kIBH2kRe9Hm8lIXFtkyOZnzCRl80VIaowXYDcN0VuxQnKnPRIv-e7VNdDCTe8mmt8EQnkjOii6C-YAWasQpKvB2F2O3p5dMXJ76BkszdYtlZ7xn3NmCKHLM8hwjbtQrzfQijH2ReKDTe5bfgSygkObOc96IoCg1FCsZCZBz4Ve703EInxU55RS7ghp7gF8Uph_GAK1HnIQnKR0S_P7iUiE3DDJGgAWnYOMnq_UYCWpyhqdvUYonJ9UXmliBGEZq6JKunRrmuavsr559roSLs4XTagYXDgC0BpNMa4FEqgdeXObi2Rv_sEiIEZ3GsivMbfNPOusejDXMEE1FaJdANyVLJnU1NVs_C6AUSPjdA6nxO_TvvEAnAdoah59lqrk0FHVsI87sga2Z-O1ChL4vXOz3PiX_Qe7zqGAueQJ7nGwyMM3EufYzE3RX3xWVuz4aKNHDAJeE20347lqyPAvcflQjLjIBKUJ-Uy_IxD_2y7ZIBZjoJh1RnCS6nohML2f2UWM_G0UQhJbt0DZc4XrUyiwwX71i-yDaeb1DfvL6qlEgUUrjIvnvaK">MindBody GLP-1 System&#x2122;</a>, known as the MB System&#x2122;, on activating GLP-1 production.&#x2A;&nbsp;
The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements for all other markets in which LifeVantage operates. The study on the international formula, similar to the one completed on the US formula prior to its launch, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation.
Key genes involved in the production and regulation of GLP-1 and associated neuropeptides were thoroughly examined, including:&nbsp; &nbsp;
<ul>
<li>GCG: Directs the production of Proglucagon, a precursor protein essential for GLP-1 synthesis.&nbsp;</li>
<li>GLP1R: Facilitates the creation of receptors that GLP-1 binds to, enabling its biological activity.&nbsp;</li>
<li>DPP-4: An enzyme that degrades GLP-1, reducing the amount available in the body.&nbsp;</li>
<li>PYY and PPY: Support the production of neuropeptides that work with GLP-1 along the gut-brain axis to regulate hunger signals.&nbsp;</li>
</ul>
The study used ELISA (Enzyme-Linked Immunosorbent Assay) to quantify total GLP-1 production, complemented by fluorescent microscopy to visualize the outcomes. The research focused on determining the synergistic potential of the active blends from the two-product system, which was designed to enhance the body's GLP-1 production through a dual mechanism: direct activation of L-cells with a proprietary blend of five naturally-derived ingredients and optimization of the gut microbiome environment using resistant starches.&#x2A;&nbsp;

LifeVantage Announces Completion Of Study On MindBody GLP-1 System. The Study Focused On L-Cells And Key Genes In GLP-1 Production Using ELISA And Fluorescent Microscopy

Craig-Hallum analyst Alex Fuhrman initiates coverage on Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) with a Buy rating and announces Price Target of $35.

Price Target

Initiation

Analyst Ratings

Craig-Hallum Initiates Coverage On Lifevantage with Buy Rating, Announces Price Target of $35

<a href="https://www.globenewswire.com/Tracker?data=QICvUiLZeNOvfe6ZTx3s27EQ7dD4hI1hClQPV-1-39rw6P62jWvuIrW4UxkYTXClcz7J-fwcSeSdnMQ8PawaVS1kUy8179zk86G4Y9n1aQmPAiJIYp97pioLnz-4DRAYIKqDhaUUsApLUJcvIEEtf07Nf4OUrPMYeKbjXDZdg6SIU2YsU35AQzXZuCEzGjjbGABFxNCakcCUSfaFSrOHvwjxtV_OUM95u6okwf9QYB2mEwT72CqzhsFw1Fkei8DP8yQsiwQOBdgJzJM0VikYwZk5YrTAxXTX8M0CskikgaUJMJmlt9QYhmaby8-JAoJamtTZbIDZXqrgqFJFxq8fSCBg1IVanYMF6PcHImSICrEPk2VJIEDTBlBF6npaQdEEiHTPj1OCtMk0M961fU1AMfbWvTAxMA9Js2nZYl7iocjuWPfz4lusSv1kZUirQZw9DvbfYtu46-aw1e1HSpLpvpJnnSyL1BM6Z0FzWjt9G9N584A-suNw7j4WGhTVFRrG__JKKt-D5Sm2BrQSIN605sWLqGFyFahNJ9_hag8eIcY9Y3vlEzOe1JoQzuXwQatZBFlcJqRvTBFtKTT6oB7n1A==">LifeVantage Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, hosted its annual Global Kickoff on Saturday, January 11, 2025. Thousands of the company's independent Consultants around the world joined the live broadcast to celebrate the company's bold vision for 2025, which emphasized momentum, continued innovation, and international expansion of the MindBody GLP-1 System&#x2122;. The company also announced that the Philippines, Taiwan, Hong Kong, and Singapore markets will transition to the Evolve Compensation Plan on March 1, with Thailand, the final market to move to Evolve, planned for transition by the end of the fiscal year.
An energetic tone was set early in the broadcast by President and CEO Steve Fife, who introduced the 2025 theme: "Drive ERA." The theme's core message encourages Consultants to build on the momentum of the previous year, find their internal motivations, and take proactive control of their success.

Global

LifeVantage Announces 2025 Vision At Global Kickoff, Emphasizes MindBody GLP-1 System Expansion, Philippines, Taiwan, Hong Kong, Singapore To Transition To Evolve Plan On March 1, Thailand By Fiscal Year End

LifeVantage shares are trading higher after the company reported preliminary Q2 revenue and raised its FY25 revenue guidance.

LifeVantage Reports Preliminary Q2 Revenue of $67.5M vs $51.45, Up 31% YoY and 43% Sequentially, Raises FY25 Revenue Guidance to $235M-$245M vs Prior $200M-$210M (Est. $204.3M)

Health Care

Press Releases

LifeVantage Study Confirms Breakthrough Synergistic Effects of Healthy Weight Stack*

LifeVantage Launches 2025 Vision with "Drive ERA" Theme and International Expansion Plans for Evolve Compensation Plan and the MindBody GLP-1 System™

Management

LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

TrueScience® Activated Skincare Collection Recognized for Cutting-Edge Innovation, Clean Beauty Standards, and Proven Anti-Aging Results*

LifeVantage to Announce Second Quarter Fiscal Year 2025 Results on February 5, 2025

LifeVantage Announces Completion of International In Vitro Study on the MB System™

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2025

Dividends

LifeVantage Declares Quarterly Dividend

LifeVantage Announces Launch of LV360 and Evolve Compensation Plan in Philippines, Taiwan, Hong Kong, and Singapore Markets

LifeVantage Expands Global Reach with International Launch of the MB System™

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Kenvue

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

Craig-Hallum

Lake Street

Comments

Lifevantage

Noticias

Últimas noticias sobre Lifevantage (NASDAQ:LFVN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL